Tumor rejection by disturbing tumor stroma cell interactions

Journal of Experimental Medicine

Volumn 194, Issue 11, 2001, Pages 1549-1559

  Ibe, Sabrina ^a   Qin, Zhihai ^b   Schüler, Thomas ^a   Preiss, Susanne ^a   Blankenstein, Thomas ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Antiangiogenesis; Cyclophosphamid; IFN ; Tumor infiltrating macrophages; Tumor stroma

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 10;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; STROMA CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REJECTION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; FIBROSARCOMA; INTERFERON TYPE II; INTERLEUKIN-10; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PLASMACYTOMA; RECEPTORS, INTERFERON; STROMAL CELLS; TIME FACTORS;

EID: 0035803463     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.194.11.1549     Document Type: Article

References (45)

1. Similarities between tumor stroma generation and wound healing
2. Inflammation and Cancer
3. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
4. The origin and function of tumor associated macrophages
5. Genetic approaches to cancer immunotherapy
6. The murine antitumor immune response and its therapeutic manipulation
7. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
8. + effector T cells
9. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells
10. CD4-positive and B lymphocytes in transplantation immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes
11. Regulation of the macrophage content of neoplasms by chemoattractans
12. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages
13. Interleukin 10 gene transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration
14. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer
15. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor-necrosis factor, or interferon-γ
16. Cyclophosphamide (Cy) -facilitated adoptive immunotherapy of a Cy-resistant tumor. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumor burden
17. Effects of anticancer drugs on the immune system in man
18. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
19. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors
20. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors
21. + T cells in the antitumor immune response
22. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
23. + T cell-mediated tumor rejection involves inhibition of angiogenesis which is dependent on IFN-γ receptor expression by non-hematopoietic cells
24. Murine macrophages secret interferon γ upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation
25. Distribution of interferon-γ receptor in human tissues
26. The molecular cell biology of interferon-γ and its receptor
27. Immune response in mice that lack the interferon-γ receptor
28. Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration
29. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide
30. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice
31. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression
32. Interleukin 10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage-colony-stimulating-factor gene modified tumor cells
33. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing interleukin 10
34. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1
35. Autocrine production of IL-10 mediates defective IL-12 poduction and NF-kB activation in tumor-associated macrophages
36. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12
37. Evidence for the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ
38. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo
39. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo
40. Interferon-γ elicits arteriosclerosis in the absence of leukocytes
41. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
42. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
43. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
44. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells
45. Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors